Tumor News and Research

RSS

US Spine's newly launched Preference 2 Complex Spine System to treat complex spinal pathologies

US Spine is pleased to announce the commercial launch of the Preference 2 Complex Spine System. The product has been in use at select sites throughout the spring and summer, with strong clinical feedback and results. The introduction of this product has improved the company’s pedicle screw business nearly 75% compared to last year at the same time.

26 Aug 2009

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a study in the August 26 issue of JAMA.

26 Aug 2009

Tamoxifen drug poses increased risk of developing ER negative breast cancer

While long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor.

26 Aug 2009

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

A new study published by researchers at the UCLA School of Dentistry substantiates the effectiveness of measuring the microRNAs present in saliva to detect oral squamous cell carcinoma. Like hall monitors in an elementary school, microRNAs are the molecules produced by cells that simultaneously asses the behavior of multiple genes and control their activity.

25 Aug 2009

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has exceeded 90% enrollment reaching 85 patients for its pivotal Phase III Metastatic Melanoma Trial.

25 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Elevated levels of GLI1 protein linked to unfavorable prognosis and progressive stages in human breast cancer

Elevated levels of GLI1 (glioma-associated oncogene homolog 1) protein in human breast cancer are associated with unfavorable prognosis and progressive stages of disease. Researchers writing in the open access journal BMC Cancer found increased expression of GLI1 in samples taken from more advanced and less survivable tumors.

25 Aug 2009

Primary cilia can suppress or promote skin cancer

Tiny, solitary spikes that stick out of nearly every cell in the body play a central role in a type of skin cancer, new research has found. The discovery in mice shows that the microscopic structures known as primary cilia can either suppress or promote this skin cancer, depending on the mutation triggering the disease.

24 Aug 2009

New study identifies smoking as a risk factor for active TB

Smoking is a risk factor for active tuberculosis (TB) disease, according to a new study on TB incidence in Taiwan.

24 Aug 2009

Research reveals that diarrheal bacteria can cause colon cancers

Johns Hopkins scientists say they have figured out how bacteria that cause diarrhea may also be the culprit in some colon cancers. The investigators say that strains of the common Bacteroides fragilis (ETBF) dupe immune system cells into permitting runaway colon tissue inflammation, a precursor for malignant growth.

24 Aug 2009

Tiny filaments extending from cells may play a role in common malignant brain tumors

UCSF scientists have discovered that a tiny filament extending from cells, until recently regarded as a remnant of evolution, may play a role in the most common malignant brain tumor in children.

24 Aug 2009

Genway Clinical Laboratory offers ELISA-based test that detects tumor markers in blood serum

GenWay Clinical Laboratory, a US-based diagnostic company with CLIA certification, has validated a general tumor marker test in their laboratory and now offers this testing service. This is an ELISA-based assay which simply requires a small blood sample from the patient in order to quantify the amount of the tumor marker in their serum.

24 Aug 2009

Discovery of mutation in AIP gene associated with acromegaly

An indigenous family living in a mountainous area of Malaysian Borneo helped Van Andel Research Institute (VARI) researchers to discover information about genetic mutations associated with acromegaly, a form of gigantism that often results in enlarged hands, feet, and facial features.

24 Aug 2009

Brits defend National Health Service against U.S. criticism

The United Kingdom's National Health System enters into the health care debate amid comparisons of the British and American health care systems. Meanwhile, British politicians defend NHS against critics.

23 Aug 2009

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein-a cancer vaccine-that will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.

21 Aug 2009

AMDL Diagnostics to focus on in vitro diagnostic cancer tests

AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced the inauguration of AMDL Diagnostics Inc. (ADI), a new wholly-owned subsidiary that will focus on the research, development, manufacture and international sales of Onko-Sure(TM)-- AMDL's proprietary, regulatory approved in vitro diagnostic (IVD) cancer test.

21 Aug 2009

Coping with burn injuries

More than half a million Americans are treated for burn injuries every year, but many do not have the specific skills necessary to cope with the experience of living with a burn injury after they leave the hospital.

20 Aug 2009

Advaxis awarded $210,000 for development of a dual antigen vaccine

Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been awarded a $210,000 grant from the US National Institute of Health (NIH) to develop a single bioengineered Lm vaccine to deliver two different antigen-adjuvant proteins.

20 Aug 2009

Varian Medical Systems to equip a new proton therapy center in Sweden

Varian Medical Systems today announced it has been selected to equip a new proton therapy center in Sweden. In a ceremony conducted by Swedish authorities yesterday following a public tender, Varian was named to supply an estimated $60 million in products for Skandionkliniken, a new national proton therapy center owned by a consortium of seven of Sweden's counties.

20 Aug 2009

Helicos Genetic Analysis System to aid Ontario Institute for Cancer Research scientists in the study of cancer genomics

Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies, today announced the placement of a Helicos™ Genetic Analysis System at the Ontario Institute for Cancer Research (OICR) with Drs. Tom Hudson and John McPherson.

20 Aug 2009

Tumor News and Research

US Spine's newly launched Preference 2 Complex Spine System to treat complex spinal pathologies

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Tamoxifen drug poses increased risk of developing ER negative breast cancer

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Elevated levels of GLI1 protein linked to unfavorable prognosis and progressive stages in human breast cancer

Primary cilia can suppress or promote skin cancer

New study identifies smoking as a risk factor for active TB

Research reveals that diarrheal bacteria can cause colon cancers

Tiny filaments extending from cells may play a role in common malignant brain tumors

Genway Clinical Laboratory offers ELISA-based test that detects tumor markers in blood serum

Discovery of mutation in AIP gene associated with acromegaly

Brits defend National Health Service against U.S. criticism

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

AMDL Diagnostics to focus on in vitro diagnostic cancer tests

Coping with burn injuries

Advaxis awarded $210,000 for development of a dual antigen vaccine

Varian Medical Systems to equip a new proton therapy center in Sweden

Helicos Genetic Analysis System to aid Ontario Institute for Cancer Research scientists in the study of cancer genomics

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News